The flagellin protein is an immunodominant spirochetal antigen which induces high antibody titers early after development of erythema migrans (3, 7, 14) . By using flagellinenriched protein fractions (5, 13) or Western immunoblotting (6, 11, 15, 16, 26) , it was revealed that some sera from healthy donors or from patients with other diseases recognized the 41-kDa flagellar protein. Therefore, the existence of epitopes on the flagellar protein homologous with other bacterial flagellins is obvious, as shown previously (24) . On the other hand, borrelia-specific monoclonal antibody (MAb) H9724 binds to flagellar protein and is the only MAb characterized so far that does not cross-react with other flagellins, indicating that this MAb binds to a borrelia-specific epitope on the flagellin (4). It is not known whether such a genus-specific epitope is recognized by sera of patients with Lyme disease. Collins and Pelz (6), using sera from patients with arthritis, were not able to identify such epitopes with truncated flagellar protein expressed in Escherichia coli. They detected only antibodies to the first 90 amino acids (aa) in patients with Lyme disease and in some healthy donors, whereas MAb H9724 was mapped in the C-terminal 246 aa (6) .
MAb H9724 as well as antibodies from patients with Lyme disease were reported to cross-react with human tissues and myelin (1, 8, 23, 25) . Autoreactive T cells in the cerebrospinal fluid of patients with Lyme disease could be demonstrated (17) . However, little information is available about the epitope responsible for this autoimmune mechanism.
To elucidate the immune response to the flagellar protein ofBorrelia burgdorferi, we used overlapping decapeptides to determine continuous epitopes of patients with Lyme disease in different stages. This study was carried out for three reasons: (i) to identify the precise location of common and B. burgdorferi-specific epitopes, (ii) to demonstrate different B-cell epitopes in early and late manifestations of Lyme disease, and (iii) to localize a possible autoreactive epitope.
Multiple oligopeptide syntheses (decapeptides) were performed on two blocks each with 96 prederivatized pins corresponding to the 96 wells of a microtiter plate, following * Corresponding author. the synthesis schedule recommended by Cambridge Research Biochemicals Ltd., Cambridge, England, according to Merifield (18) . All peptides were synthesized concurrently by stepwise elongation of the peptide chain from the C to the N terminus. Temporary protection of the incoming amino acids was afforded by the Fmoc/t-butyl protecting group combination, with coupling being effected by use of the highly activated pentafluorophenyl and 1-hydroxy-benzotriazole esters.
The amino acid sequence of the B. burgdorferi flagellin strain B31 (10) starts at decapeptide 3 with the sequence MIINHNTSAI. Each subsequent peptide overlapped with the previous one by eight aa, ending with decapeptide 190 (VPQYVLSLLR). Decapeptides 1 and 192 are oligopeptides of TM/gp41 of human immunodeficiency virus type 1 (IWGCSGKCIC) (19) , and decapeptides 2 and 191 are derived from human immunodeficiency virus type 2 gp36 (SWGCAFRQVC) (12) . Decapeptides 1, 2, 191, and 192 were incubated with a human immunodeficiency virus type 1-positive serum specimen which served as an internal control and standard for the enzyme reaction for every test run, knowing that this serum shows a constant positive reaction with the gp4l-derived decapeptides (no. 1 and 192) but not with decapeptides 2 and 191.
Incubation and regeneration of the peptide scan followed procedures described in detail recently (20, 21 The sera used in this study were obtained from patients with clinically and serologically confirmed Lyme disease. Lyme serum 1 (Fig. la) was prepared from a woman with acrodermatitis chronica atrophicans (ACA) whose clinical course was described previously (22 (Fig. 1) , one epitope A in the N-terminal part and one epitope C in the C-terminal region. Therefore, epitope B might act in serological tests as a prognostic marker and a control for therapeutic progress in the late stages of Lyme disease.
Our results taken together with the results of others who reported a cross-reaction between MAb H9724 and myelin and other human tissues (1), the presence of antimyelin antibodies in the cerebrospinal fluid (2, 23) with the highest number of B cells secreting such antibodies in patients with severe signs of central nervous system involvement (2) and the observation that antibodies to other proteins of B. burgdorferi or other epitopes of the flagellin showed no cross-reaction with myelin (1), implicate a role for the identified B-cell epitope in the pathogenesis of Lyme borreliosis.
Autoimmunity and antigen mimicry in Lyme borreliosis may be due to the identified epitope recognized by human sera of severe Lyme disease and the borrelia-specific MAb H9724 cross-reacting with myelin and other human tissues. The hypothesis is supported by the fact that our patient with tertiary neuroborreliosis partially recovered after treatment with corticosteroids and in parallel her antibody titer to flagellin decreased; 1 year later, the patient no longer has antibodies against this protein detectable by Western blot. Also, our study gives an explanation of some serodiagnostic difficulties and a better understanding of the immune re-sponse to B. burgdorferi. The common epitopes described and the possible nonspecific binding of immunoglobulins to the N-terminal part of the flagellar protein may be due to some of the observed false-positive reactions in a variety of test systems.
We are indebted to G. Pauli (AIDS Zentrum, Berlin) for stimulating discussions.
This study was supported by Berlin Forschung grant 12/89 and by a grant of the Standige Kommision fur Forschung und wissenschaftlichen Nachwuchs (FNK) der Freien Universitiit Berlin.
